{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:01:17Z","timestamp":1793664077058,"version":"4.5.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009054","name":"U.S. President\u2019s Emergency Plan for AIDS Relief","doi-asserted-by":"publisher","award":["AID-674-A-12-00029"],"award-info":[{"award-number":["AID-674-A-12-00029"]}],"id":[{"id":"10.13039\/100009054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009054","name":"U.S. President\u2019s Emergency Plan for AIDS Relief","doi-asserted-by":"publisher","award":["72067419CA00004"],"award-info":[{"award-number":["72067419CA00004"]}],"id":[{"id":"10.13039\/100009054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009054","name":"U.S. President\u2019s Emergency Plan for AIDS Relief","doi-asserted-by":"publisher","award":["674-A-00-09-00018-00"],"award-info":[{"award-number":["674-A-00-09-00018-00"]}],"id":[{"id":"10.13039\/100009054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multi-drug resistant and rifampicin-resistant tuberculosis (MDR\/RR-TB) in pregnant women is a cause for concern globally; few data have described the safety of second-line anti-TB medications during pregnancy. We aim to describe TB treatment and pregnancy outcomes among pregnant women receiving second-line anti-tuberculosis treatment for MDR\/RR-TB in Johannesburg, South Africa.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective record review of pregnant women (\u2265\u200918\u00a0years) who received treatment for MDR\/RR-TB between 01\/2010\u201308\/2016 at three outpatient treatment sites in Johannesburg, South Africa. Demographic, treatment and pregnancy outcome data were collected from available medical records. Preterm birth (&lt;\u200937\u00a0weeks), and miscarriage were categorized as adverse pregnancy outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of 720 women of child-bearing age who received MDR\/RR-TB treatment at the three study sites, 35 (4.4%) pregnancies were identified. Overall, 68.7% (24\/35) were HIV infected, 83.3% (20\/24) were on antiretroviral therapy (ART). Most women, 88.6% (31\/35), were pregnant at the time of MDR\/RR-TB diagnosis and four women became pregnant during treatment.<\/jats:p>\n                <jats:p>Pregnancy outcomes were available for 20\/35 (57.1%) women, which included 15 live births (11 occurred prior to 37\u00a0weeks), 1 neonatal death, 1 miscarriage and 3 pregnancy terminations. Overall, 13\/20 (65.0%) women with known pregnancy outcomes had an adverse pregnancy outcome. Of the 28 women with known TB treatment outcomes 17 (60.7%) completed treatment successfully (4 were cured and 13 completed treatment), 3 (10.7%) died and 8 (28.6%) were lost-to-follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Pregnant women with MDR\/RR-TB suffer from high rates of adverse pregnancy outcomes and about 60% achieve a successful TB treatment outcome. These vulnerable patients require close monitoring and coordinated obstetric, HIV and TB care.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12884-021-03956-6","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T15:03:05Z","timestamp":1624892585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Treatment and pregnancy outcomes of pregnant women exposed to second-line anti-tuberculosis drugs in South Africa"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8054-0116","authenticated-orcid":false,"given":"Idah","family":"Mokhele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Jinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Berhanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thandi","family":"Dlamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"3956_CR1","volume-title":"Global Tuberculosis Report 2019","author":"World Health Organisation (WHO)","year":"2019","unstructured":"World Health Organisation (WHO). Global Tuberculosis Report 2019. Geneva: WHO; 2019. [cited on 1 July 2019] Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-report-2019."},{"key":"3956_CR2","volume-title":"Global Tuberculosis Report 2020","author":"World Health Organisation (WHO)","year":"2020","unstructured":"World Health Organisation (WHO). Global Tuberculosis Report 2020. Geneva: WHO; 2020. [cited on 1 July 2019] Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240013131."},{"issue":"1","key":"3956_CR3","first-page":"157","volume":"2017","author":"H Cox","year":"2017","unstructured":"Cox H, Dickson-Hall L, Jassat W, et al. Drug-resistant tuberculosis in South Africa: history, progress and opportunities for achieving universal access to diagnosis and effective treatment. South African Health Rev. 2017;2017(1):157\u201367.","journal-title":"South African Health Rev"},{"issue":"4","key":"3956_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.7196\/SAMJ.2016.v106i4.10205","volume":"106","author":"K Schnippel","year":"2016","unstructured":"Schnippel K, Ndjeka N, Conradie F, et al. A call to action: Addressing the reproductive health needs of women with drug-resistant tuberculosis. S Afr Med J. 2016;106(4):333\u20134.","journal-title":"S Afr Med J"},{"issue":"4","key":"3956_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.5152\/TurkThoracJ.2018.17062","volume":"19","author":"R Laniado-Labor\u00edn","year":"2018","unstructured":"Laniado-Labor\u00edn R, Carrera-L\u00f3pez K, Hern\u00e1ndez-P\u00e9rez A. Unexpected pregnancy during treatment of multidrug-resistant tuberculosis. Turk Thoracic J. 2018;19(4):226\u20137.","journal-title":"Turk Thoracic J"},{"issue":"11","key":"3956_CR6","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/cid\/cis732","volume":"55","author":"JS Mathad","year":"2012","unstructured":"Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clin Infect Dis. 2012;55(11):1532\u201349.","journal-title":"Clin Infect Dis"},{"key":"3956_CR7","volume-title":"Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk","author":"GG Briggs","year":"2012","unstructured":"Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 9th ed. Philadelphia: Lippincott Williams and Wilkins; 2012.","edition":"9"},{"issue":"05","key":"3956_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1055\/s-2007-993948","volume":"15","author":"R Figueroa-Damian","year":"1998","unstructured":"Figueroa-Damian R, Arredondo-Garcia J. Pregnancy and tuberculosis: influence of treatment on perinatal outcome. Am J Perinatol. 1998;15(05):303\u20136.","journal-title":"Am J Perinatol"},{"key":"3956_CR9","unstructured":"National Department of Health South Africa. Management of Rifampicin-Resisitant Tuberculosis: A Clinical Reference Guide 2019. [cited on 1july 2019 ] Available from: https:\/\/tbsouthafrica.org.za\/resources\/management-rifampicin-resistant-tuberculosis-clinical-reference-guide"},{"key":"3956_CR10","unstructured":"World Health Organisation (WHO). Consolidated guidelines on drug-resistant tuberculosis treatment Geneva: WHO 2019. [cited on 1 July 2019 ] Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/311389\/9789241550529-eng.pdf?ua=1"},{"key":"3956_CR11","unstructured":"National Department of Health South Africa. Multi-drug resistant tuberculosis: Introduction of New Drugs and Drug Regimens for the Management of Drug-Resistant Tuberculosis in South Africa: Policy Framework. Pretoria: 2015. [cited on 1july 2019 ] Available from: https:\/\/www.nicd.ac.za\/assets\/files\/Introduction%20of%20new%20drugs%20and%20drug%20regimens%20for%20the%20management%20of%20drug%20resistant%20TB%20in%20SA%20-%202015.pdf"},{"key":"3956_CR12","unstructured":"National Department of Health South Africa. Management of Drug-Resistant Tuberculosis: Policy Guidelines. Pretoria 2011. [cited on 1july 2019 ] Available from: https:\/\/www.nicd.ac.za\/assets\/files\/MANAGEMENT%20of%20drug%20resistant%20TB%20guidelines.pdf"},{"key":"3956_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa189.pmid:32141495","author":"M Loveday","year":"2020","unstructured":"Loveday M, Hughes J, Sunkari B, Master I, Hlangu S, Reddy T, et al. Maternal and infant outcomes among pregnant women treated for multidrug\/rifampicin-resistant tuberculosis in South Africa. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa189.pmid:32141495.","journal-title":"Clin Infect Dis"},{"key":"3956_CR14","unstructured":"National Department of Health South Africa. Interim Clinical Guidance for the Implementation of Injectable-free Regimens for Rifampicin-resistant Tuberculosis in Adults, Adolescents and Children. 2018. [cited on 1july 2019 ] Available from: https:\/\/tbsouthafrica.org.za\/sites\/default\/files\/Interim%20Clinical%20Guidance%20for%20the%20Implementation%20of%20Injectable-Free%20Regimens%20for%20Rifampicin-Resistant%20Tuberculosis%20in%20Adults%2C%20Adolescents%20and%20Children.pdf"},{"key":"3956_CR15","unstructured":"Cox H, Dickson-Halli L, Jassat W et al. Drug-resistant tuberculosis in South Africa: history, progress and opportunities for achieving universal access to diagnosis and effective treatment. 2017. [cited on 1july 2019 ] Available from: https:\/\/www.hst.org.za\/publications\/South%20African%20Health%20Reviews\/15_Drug_resistant%20tuberculosis%20in%20South%20Africa_history_progress%20and%20opportunities.pdf."},{"key":"3956_CR16","unstructured":"World Health Organisation (WHO). Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: 2014. [cited on 1july 2019 ] Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/130918\/9789241548809_eng.pdf?sequence=1"},{"key":"3956_CR17","unstructured":"National Institute of Allergy and Infectious Diseases, US Department of Health and Human Services. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. Geneva: 2014. [cited on 1 July 2019] Available from: https:\/\/www.rscniaidnihgov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf. 2.1 ed2017."},{"key":"3956_CR18","volume-title":"The use of the WHO-UMC system for standardised case causality assessment","author":"World Health Organisation (WHO)","year":"2014","unstructured":"World Health Organisation (WHO). The use of the WHO-UMC system for standardised case causality assessment. Geneva: Uppsala: The Uppsala Monitoring Centre 2005; 2014. [cited on 1 July 2019] Available from: https:\/\/www.who.int\/publications\/m\/item\/WHO-causality-assessment."},{"key":"3956_CR19","unstructured":"World Health Organisation (WHO). Definitions and reporting framework for tuberculosis 2013 revision. Geneva: 2013. [cited on 1july 2019 ] Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/79199\/9789241505345_eng.pdf?sequence=1"},{"key":"3956_CR20","unstructured":"National Department of Health South Africa. Guidelines for Maternity Care in South Africa: A manual for clinics, community health centres and district hospitals. Pretoria: 2015. [cited on 1july 2019 ] Available from: http:\/\/www.kznhealth.gov.za\/family\/Maternal-Care-Guidelines-2015.pdf."},{"key":"3956_CR21","unstructured":"World Health Organisation (WHO). International classification of diseases and related health problems. Geneva: 2010. [cited on 1july 2019 ] Available from: https:\/\/icd.who.int\/browse11\/l-m\/en"},{"issue":"10","key":"3956_CR22","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1086\/598191","volume":"48","author":"E Palacios","year":"2009","unstructured":"Palacios E, Dallman R, Mu\u00f1oz M, et al. Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima. Peru Clin Infect Dis. 2009;48(10):1413\u20139.","journal-title":"Peru Clin Infect Dis"},{"issue":"1","key":"3956_CR23","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/S2214-109X(18)30451-0","volume":"7","author":"S Chawanpaiboon","year":"2019","unstructured":"Chawanpaiboon S, Vogel JP, Moller A-B, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Glob Health. 2019;7(1):e37\u201346.","journal-title":"Lancet Glob Health"},{"issue":"5","key":"3956_CR24","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1093\/ije\/dyx136","volume":"46","author":"TR Malaba","year":"2017","unstructured":"Malaba TR, Phillips T, Le Roux S, Brittain K, Zerbe A, Petro G, et al. Antiretroviral therapy use during pregnancy and adverse birth outcomes in South African women. Int J Epidemiol. 2017;46(5):1678\u201389.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"3956_CR25","first-page":"1","volume":"20","author":"UC Mehta","year":"2019","unstructured":"Mehta UC, Van Schalkwyk C, Naidoo P, Ramkissoon A, Mhlongo O, Maharaj NR, et al. Birth outcomes following antiretroviral exposure during pregnancy: Initial results from a pregnancy exposure registry in South Africa. Southern Afr J HIV Med. 2019;20(1):1\u201312.","journal-title":"Southern Afr J HIV Med"},{"issue":"1","key":"3956_CR26","first-page":"133","volume":"2019","author":"N Rhoda","year":"2019","unstructured":"Rhoda N, Malaba T, Goga A, Kauchali S, Ramokolo V. A landscape analysis of preterm birth in South Africa: systemic gaps and solutions. South African Health Rev. 2019;2019(1):133\u201344.","journal-title":"South African Health Rev"},{"issue":"11","key":"3956_CR27","doi-asserted-by":"publisher","first-page":"e0164249","DOI":"10.1371\/journal.pone.0164249","volume":"11","author":"A Bekker","year":"2016","unstructured":"Bekker A, Schaaf HS, Draper HR, Kriel M, Hesseling AC. Tuberculosis disease during pregnancy and treatment outcomes in hiv-infected and uninfected women at a referral hospital in Cape Town. PLoS ONE. 2016;11(11):e0164249.","journal-title":"PLoS ONE"},{"issue":"6","key":"3956_CR28","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/cid\/cix851","volume":"66","author":"N Salazar-Austin","year":"2018","unstructured":"Salazar-Austin N, Hoffmann J, Cohn S, Mashabela F, Waja Z, Lala S, et al. Poor obstetric and infant outcomes in human immunodeficiency virus-infected pregnant women with tuberculosis in South Africa: the Tshepiso study. Clin Infect Dis. 2018;66(6):921\u20139.","journal-title":"Clin Infect Dis"},{"key":"3956_CR29","doi-asserted-by":"publisher","first-page":"ciaa805","DOI":"10.1093\/cid\/ciaa805","volume":"20","author":"G Theron","year":"2020","unstructured":"Theron G, Brummel S, Fairlie L, et al. Pregnancy outcomes of women conceiving on antiretroviral therapy (ART) compared to those commenced on ART during pregnancy. Clin Infect Dis. 2020;20:ciaa805. https:\/\/doi.org\/10.1093\/cid\/ciaa805 Epub ahead of print. PMID: 32564058.","journal-title":"Clin Infect Dis"},{"key":"3956_CR30","volume-title":"Global Tuberculosis Report 2017","author":"World Health Organisation (WHO)","year":"2017","unstructured":"World Health Organisation (WHO). Global Tuberculosis Report 2017. Geneva: WHO; 2017. [cited on 1 July 2019] Available from: https:\/\/www.who.int\/tb\/publications\/global_report\/gtbr2017_main_text.pdf."},{"issue":"7","key":"3956_CR31","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/jac\/dkx107","volume":"72","author":"K Schnippel","year":"2017","unstructured":"Schnippel K, Firnhaber C, Berhanu R, et al. Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(7):1871\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"3956_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1365-2710.1987.tb00539.x","volume":"12","author":"A Mathews","year":"1987","unstructured":"Mathews A, Bailie G. Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services. J Clin Pharm Ther. 1987;12(5):273\u201391.","journal-title":"J Clin Pharm Ther"},{"issue":"9","key":"3956_CR33","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.5588\/ijtld.18.0626","volume":"23","author":"M Buziashvili","year":"2019","unstructured":"Buziashvili M, Mirtskhulava V, Kipiani M, Blumberg H, Baliashvili D, Magee M, et al. Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia. Int J Tuberc Lung Dis. 2019;23(9):1005\u201311.","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-021-03956-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-021-03956-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-021-03956-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T15:04:07Z","timestamp":1624892647000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-021-03956-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3956"],"URL":"https:\/\/doi.org\/10.1186\/s12884-021-03956-6","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,28]]},"assertion":[{"value":"4 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (Wits HREC M170644). Additionally, the necessary institutional approvals were obtained from participating study sites for the study and to access the raw data. A waiver of informed consent was granted as the study was a retrospective medical record review of routinely collected data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interests exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"453"}}